Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Summary

Evotec and Plectonic entered a research collaboration to explore combining Evotec's BiTco costimulatory CD2 bispecifics platform with Plectonic's LOGIBODY® DNA-protein immunotherapy technology for solid tumor treatment. The collaboration aims to validate the combined approach for enhancing T cell activation.